FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2890192392> ?p ?o ?g. }

• W2890192392 abstract "e21635 Background: Nimotuzumab is a humanized IgG1 monoclonal antibody against the EGFR extracellular domain that has been evaluated in solid tumors as a single agent or in combination with chemotherapy and radiation. However when used without radiation, its always used in adjunct to chemotherapy. With encouraging results of other EGFR monoclonal antibodies as single agent therapies, we explored the possibility of using Nimotuzumab as single agent by which we could avoid chemo related side effects. In view of the limited options availability for subjects with PS 3 and more we thought of choosing this population for analysis of Nimotuzumab as single agent palliative therapy in PS 3 and above EGFR expressing tumors for safety and efficacy Methods: Details of the 38 subjects with pre-treated advanced refractory or progressive solid tumors having PS of more than 2 were evaluated. Nimotuzumab was administered weekly at 200 mg/m2 as single agent for 4 weeks (induction phase) and patients were stratified into those with improved PS and those without. The subjects without PS improvement were continued on the single agent and those with improvement were offered additional chemotherapy . Nimotuzumab could be continued beyond disease progression. Results: Out of 38 patients, 18 had improvement in the PS and were offered chemotherapy later. 16 patients had stable PS and disease. 3 subjects were lost to follow up and 1 patient did not continued. The median number of nimotuzumab applications was 6 (2–11) in the induction phase and the median chemotherapy cycles were 3 (1-6). No toxicity occurred during induction phases (single agent nimotuzumab) and during chemotherapy the Grade II/IV toxicities were observed in 6 (33%) cases predominantly cytopeneas, neuropathy and diarrhea. The median PFS was 142 days (95% CI, 84 to 182), and the median improvement in QOL was 6 points on a scale of 30. Conclusions: Nimotuzumab is well tolerated and may have a role in the treatment of advanced cancers as a single agent in patients with poor performance status. 47% of the patients who are otherwise not eligible for chemo became eligible and had better QOL and longer PFS [compared to historical controls]" @default.
• W2890192392 created "2018-09-27" @default.
• W2890192392 creator A5017945905 @default.
• W2890192392 creator A5037879735 @default.
• W2890192392 creator A5054890408 @default.
• W2890192392 date "2017-05-20" @default.
• W2890192392 modified "2023-09-27" @default.
• W2890192392 title "Nimotuzumab as a single agent palliative therapy in performance score 3 and above in EGFR expressing tumors." @default.
• W2890192392 doi "https://doi.org/10.1200/jco.2017.35.15_suppl.e21635" @default.
• W2890192392 hasPublicationYear "2017" @default.
• W2890192392 type Work @default.
• W2890192392 sameAs 2890192392 @default.
• W2890192392 citedByCount "0" @default.
• W2890192392 crossrefType "journal-article" @default.
• W2890192392 hasAuthorship W2890192392A5017945905 @default.
• W2890192392 hasAuthorship W2890192392A5037879735 @default.
• W2890192392 hasAuthorship W2890192392A5054890408 @default.
• W2890192392 hasConcept C121608353 @default.
• W2890192392 hasConcept C126322002 @default.
• W2890192392 hasConcept C143998085 @default.
• W2890192392 hasConcept C2776055544 @default.
• W2890192392 hasConcept C2779438470 @default.
• W2890192392 hasConcept C2781230642 @default.
• W2890192392 hasConcept C71924100 @default.
• W2890192392 hasConceptScore W2890192392C121608353 @default.
• W2890192392 hasConceptScore W2890192392C126322002 @default.
• W2890192392 hasConceptScore W2890192392C143998085 @default.
• W2890192392 hasConceptScore W2890192392C2776055544 @default.
• W2890192392 hasConceptScore W2890192392C2779438470 @default.
• W2890192392 hasConceptScore W2890192392C2781230642 @default.
• W2890192392 hasConceptScore W2890192392C71924100 @default.
• W2890192392 hasLocation W28901923921 @default.
• W2890192392 hasOpenAccess W2890192392 @default.
• W2890192392 hasPrimaryLocation W28901923921 @default.
• W2890192392 hasRelatedWork W1965970474 @default.
• W2890192392 hasRelatedWork W1967712500 @default.
• W2890192392 hasRelatedWork W2065254819 @default.
• W2890192392 hasRelatedWork W2206993150 @default.
• W2890192392 hasRelatedWork W2266631974 @default.
• W2890192392 hasRelatedWork W2281489466 @default.
• W2890192392 hasRelatedWork W2361331618 @default.
• W2890192392 hasRelatedWork W2386942209 @default.
• W2890192392 hasRelatedWork W2416474089 @default.
• W2890192392 hasRelatedWork W2589321044 @default.
• W2890192392 hasRelatedWork W2604316224 @default.
• W2890192392 hasRelatedWork W2606133764 @default.
• W2890192392 hasRelatedWork W2965052056 @default.
• W2890192392 hasRelatedWork W3001236019 @default.
• W2890192392 hasRelatedWork W3120850158 @default.
• W2890192392 hasRelatedWork W3124478254 @default.
• W2890192392 hasRelatedWork W85811970 @default.
• W2890192392 hasRelatedWork W2181906974 @default.
• W2890192392 hasRelatedWork W2844850065 @default.
• W2890192392 hasRelatedWork W2914720586 @default.
• W2890192392 isParatext "false" @default.
• W2890192392 isRetracted "false" @default.
• W2890192392 magId "2890192392" @default.
• W2890192392 workType "article" @default.